Risks of dependence on benzodiazepine drugs: a major problem of long term treatment

Heather Ashton

Phlegmatic people dislike taking benzodiazepine drugs. In those with low anxiety traits benzodiazepines are dysphoric and may paradoxically increase anxiety.\(^1\) In normal subjects benzodiazepines improve performance under experimental stress but worsen it under conditions of low stress.\(^2\) Benzodiazepines relieve preoperative anxiety in patients with high anticipatory anxiety but not in those with low anticipatory anxiety.\(^3\) Thus like β receptor blocking agents benzodiazepines require some underlying tone upon which to exert their anxiolytic effects. In general, the greater the anxiety the greater the anxiolytic efficacy.

It follows that most people who take benzodiazepines are anxious. In students a history of prescribed benzodiazepines correlates with a high anxiety trait.\(^4\) Long term users likewise have high scores for neurotism.\(^5\) These findings apply when benzodiazepines are used both as anxiolytic and as hypnotic agents. Thus people who take and keep on taking benzodiazepines are a self selected population with high anxiety traits or states.

Reasons for dependence on benzodiazepines

Dependence on benzodiazepines in the sense that users require the drugs for psychological comfort and suffer withdrawal symptoms when they stop taking them develops rapidly.\(^2\) The same patients who find benzodiazepines efficacious are also prone to dependence and to withdrawal effects, which are themselves largely manifestations of anxiety.

This vulnerability occurs for several reasons. Firstly, anxious people are more likely to complain of symptoms.\(^6\) Secondly, long term users of benzodiazepines tend to have poor abilities in coping with stress. The pharmacological basis for both anxiety and a poor ability to cope with stress may be low activity in limbic system pathways utilising γ-aminobutyric acid\(^7\) or high activity in those utilising serotonin,\(^8\) or both. Such activity is counteracted by benzodiazepines.\(^9\) Benzodiazepines, however, impair learning of strategies to cope with stress, such as behavioural treatment for agoraphobia.\(^10,11\) Other characteristics (passive-dependent personality, resourcelessness\(^12\)) also increase the vulnerability to withdrawal symptoms and the motivation for continued use. Benzodiazepine deprivation in such users leaves them unprotected from stress and re-exposes their limitations of coping.

Finally, anxious people may be innately sensitive to punishing stimuli.\(^13\) Benzodiazepines are “depunishing” drugs. Even in animals they protect against punishing stimuli\(^14\) and are taken therapeutically by many people as protective drugs.\(^15\) In contrast, those who take benzodiazepines at high doses for kicks\(^16\) form a different population, innately less sensitive to punishment\(^17\) that also tends to abuse other drugs\(^17\) (see box).

Withdrawal syndrome with benzodiazepines

The overall incidence of a withdrawal syndrome after long term therapeutic doses of benzodiazepines is unknown. Estimates vary with the population studied, the duration of drug use, the rate of withdrawal, the length of follow up, and the definition. Lader and colleagues reported a 100% incidence: all patients experienced withdrawal symptoms (increased anxiety, other psychological and somatic symptoms, and perceptual disturbances),\(^18\) although slow withdrawal minimises symptoms.\(^19\) Tyrer et al estimated that only 30-45% experienced true withdrawal symptoms, defined as a temporary increase in anxiety to half or more above prewithdrawal values or the development of two or more new symptoms (”pseudowithdrawal” occurred in some patients who thought that they were withdrawing).\(^20\) Others report similar results.\(^21\)

Withdrawal criteria based on differences from prewithdrawal measures, however, underestimate the true incidence. I have observed that long term users of benzodiazepines develop further symptoms while taking the drugs.\(^22\) These include increasing anxiety and also paraesthesiae and perceptual disturbances, new symptoms generally associated with withdrawal.\(^23\) These symptoms may result from tolerance to some effects of benzodiazepines so that a withdrawal syndrome emerges despite continued drug use. Supporting this observation is the fact that increasing the dose of benzodiazepines temporarily alleviates symptoms.\(^24\) A large escalation in dose is reputedly rare,\(^25\) no doubt...
because benzodiazepines are medically prescribed to patients who are generally compliant. Nevertheless, 7-10 mg lorazepam daily is not uncommon (equivalent to 75-100 mg diazepam). Withdrawal symptoms occurring during long term use are more noticeable with potent benzodiazepines that are rapidly eliminated. Patients taking lorazepam or alprazolam commonly experience craving or dysphoria between doses, and daytime withdrawal effects from the use of triazolam as a hypnotic are well recognized. Thus the motivation to use benzodiazepines for anxiolysis or hypnosis gradually merges with the need to avoid withdrawal effects. For this reason it may be impossible to measure withdrawal effects precisely.

Recently Murphy et al broadened their withdrawal criteria to include a temporary increase in anxiety to less than initial values. In this study ratings before benzodiazepine were available and the incidence of withdrawal symptoms was again 30%. Diazepam was, however, given for only six weeks and the results may not apply to those who use it for longer. Furthermore, many long term users (46 out of 86 in one study) decline to undertake withdrawal and many drop out (18 of the remaining 40) because of fear or experience of withdrawal. Taking account of these subjects would substantially raise the apparent incidence.

Pharmacological mechanisms
The pharmacodynamic mechanism of benzodiazepine tolerance and dependence is probably homeostatic down regulation of γ-amino butyric acid and benzodiazepine receptors in the limbic system. Once this has occurred, withdrawal of the drug results in a state of underactivity of pathways utilising γ-amino butyric acid with a pattern of unopposed neuronal excitation characteristic of benzodiazepine withdrawal and anxiety states. Similar brain mechanisms mediate the psychological and somatic symptoms of both conditions, which are in many respects inseparable.

Lader notes that even non-anxious people may develop benzodiazepine withdrawal symptoms, although they may be less prone to do so. There may be a population of stable people who discard benzodiazepines without difficulty when a temporary stress has passed. I suggest, however, that most people who continue to use benzodiazepines are dependent on the drugs for enhancement of the effects of γ-amino butyric acid. All will suffer withdrawal symptoms unless they withdraw slowly and simultaneously learn alternative strategies of coping. Long term control of anxiety probably requires learned changes in endogenous γ-amino butyric acid transmission rather than the imposition of an exogenous cover up with benzodiazepines.

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Type of premorbid personality</th>
<th>Normal</th>
<th>Dependent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose</td>
<td>Low</td>
<td>Variable</td>
<td>Regular</td>
</tr>
<tr>
<td>Frequency</td>
<td>Intermittent</td>
<td>Short</td>
<td>Long</td>
</tr>
<tr>
<td>Duration of treatment</td>
<td>Precise dependence on prescribed psychotropic drugs</td>
<td>Rare</td>
<td>Determined by prescriber</td>
</tr>
<tr>
<td>Nature of benzodiazepine</td>
<td></td>
<td>Common</td>
<td>Determined by prescriber</td>
</tr>
</tbody>
</table>

Peter Tyrer
continued from page 102

is excluded the features associated with dependence—high dosage, long duration of treatment, and previous dependence on psychotropic drugs—are avoided and the prescription becomes short term, low dosage, and comparatively free of risk (table). Doctors need to realise that benzodiazepines now have no value in long term prescribing. These drugs should not be given for longer than four weeks; if given for longer they are less effective than antidepressants and psychological procedures such as cognitive therapy and self help packages. They should be confined to short term intervention when rapid relief of anxiety and insomnia is considered to be essential. In making the decision to prescribe benzodiazepines doctors need to diagnose symptoms, circumstances, and person. If they do this successfully they have no reason to fear dependence.

1 Parrott AG, Kendrige P. Personal constructs of anxiety under the 1,5 benzodiazepine clozapam related to trait anxiety levels of the personality. Psychopharmacology 1980;78:332-7.